Core Viewpoint - Yiju Medical (06929) announced a special dividend of HKD 0.15 per share to be distributed on October 6, 2025 [1] Company Summary - The company is set to distribute a special dividend, indicating a positive cash flow situation and potential shareholder value enhancement [1]

發行人所發行上市權證/可轉換債券的相關信息 發行人所發行上市權證/可轉換債券 不適用 其他信息 其他信息 不適用 發行人董事 於本公告日期，董事會包括執行董事錢永勛先生、劉桂禎女士及陳泳成先生；非執行董事梁鼎新先生及周伊博士；以及獨立非執行 董事陳業強先生、樓家強先生BBS、MH、JP及譚麗芬醫生。 第 2 頁 共 2 頁 v 1.1.1 第 1 頁 共 2 頁 v 1.1.1 EF001 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 業聚醫療集團控股有限公司 | | 股份代號 | 06929 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 宣派特別股息及暫停辦理股份過戶登記手續 | | 公告日期 | 2025年8月15日 | | 公告狀態 | 新公告 | | 股息信息 | | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 OrbusNeich Medical Group Holdings Limited 業聚醫療集團控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6929） 截至2025年6月30日止六個月 中期業績公告 董事會欣然宣佈本集團截至2025年6月30日止六個月的中期簡明綜合業績，連同截至2024年6月 30日止六個月的比較數字。 財務摘要 | | 截至6月30日止六個月 | | | | --- | --- | --- | --- | | | 2025年 | 2024年 | 變動 | | | 千美元 | 千美元 | | | | （未經審計） | （未經審計） | | | 經營業績 | | | | | 收入 | 83,550 | 78,910 | 5.9% | | 銷售成本 | (27,653) | (23,134) | 19.5% | | 毛利 | 55,897 | 55,776 | 0.2% | ...

格隆汇8月4日丨业聚医疗(06929.HK)宣布，谨定于2025年8月15日（星期五）举行董事会会议，藉以 （其中包括）考虑及批准公司及其附属公司截至2025年6月30日止的中期业绩及其刊发，考虑派发中期 股息（如有）及处理其他任何事务。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 香港，2025年8月4日 於本公告日期，董事會包括執行董事錢永勛先生、劉桂禎女士及陳泳成先生；非執行董事梁鼎新先 生及周伊博士；以及獨立非執行董事陳業強先生、樓家強先生 BBS、MH、JP 及譚麗芬醫生。 董事會會議召開日期 業聚醫療集團控股有限公司（「本公司」）董事會（「董事會」）茲通告謹定於二零二五年 八月十五日（星期五）舉行董事會會議，藉以（其中包括）考慮及批准本公司及其附屬 公司截至二零二五年六月三十日止之中期業績及其刊發，考慮派發中期股息（如有） 及處理其他任何事務。 承董事會命 業聚醫療集團控股有限公司 董事長、執行董事兼首席執行官 錢永勛先生 OrbusNeich Medical Group Holdings Limited 業聚醫療集團控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6929） ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 業聚醫療集團控股有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06929 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,200,000,000 | USD | | 0.0005 | USD | | 600,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,200,000,000 | USD | | 0.0005 | USD | | 600,000 | 本月底法定/註冊股本 ...

Core Viewpoint - The PTCA balloon industry in China is experiencing steady growth due to the increasing prevalence of cardiovascular diseases, the expansion of coronary intervention treatments, and the rise of domestic medical device manufacturers. The market size is projected to grow from 1.059 billion yuan in 2021 to 1.366 billion yuan in 2024, with expectations to exceed 2.274 billion yuan by 2030 [1][11]. Industry Overview - PTCA balloons are medical devices used in cardiovascular interventions to dilate narrowed or blocked coronary arteries, improving blood flow and myocardial supply [1]. - The industry chain consists of upstream raw materials and equipment supply, midstream production, and downstream application in various medical institutions for treating cardiovascular diseases [2]. Industry Environment - The incidence of coronary artery disease (CAD) is rising in China, with the number of patients increasing from 25.272 million in 2020 to 27.953 million in 2024, and projected to exceed 30 million by 2030 [4]. - The mortality rate for CAD has also increased significantly, indicating a growing demand for treatment options [4]. Industry Status - Percutaneous coronary intervention (PCI) is a key treatment method for CAD, with a record of 1.63 million PCI procedures performed in 2023, marking a growth rate of 26.44% [7]. - Despite the increasing number of PCI procedures, the market penetration rate in China remains low at 690.9 procedures per million people, compared to 3022.1 in the U.S., suggesting significant growth potential [9]. Competitive Landscape - The global PTCA balloon market is dominated by international giants like Boston Scientific and Medtronic, which hold over 60% market share, particularly in high-end drug-eluting balloons [13]. - Domestic companies account for 60% of the number of firms but only 40% of the market share, indicating a competitive landscape where local firms are striving to catch up through innovation [13]. Future Trends - The industry is witnessing significant technological innovation and product upgrades, with new polymer materials enhancing balloon performance and the introduction of drug-coated balloons reducing the risk of restenosis [19]. - The trend towards domestic substitution is accelerating, with local companies like MicroPort and Lepu Medical increasing their market share due to improved product quality and performance [20]. - The demand for PTCA balloons is expected to grow as their application expands beyond traditional coronary disease treatment to include peripheral and intracranial vascular diseases [21].

Core Insights - The data indicates significant trading volume increases for various companies, suggesting heightened investor interest and potential market movements [1][2][3][4][5] Group 1: Companies with Notable Volume Increases - 阳光能源 (00757) reported a volume ratio of 2.35, indicating strong trading activity [2] - 长城汽车 (02333) had a volume ratio of 2.21, reflecting increased investor engagement [2] - 郑煤机 (00564) showed a volume ratio of 1.92, suggesting a notable rise in trading [2] Group 2: Additional Companies with Increased Trading Activity - 万国数据-SW (09698) recorded a volume ratio of 1.83, indicating significant market interest [2] - 映恩生物-B (09606) had a volume ratio of 1.78, reflecting heightened trading activity [2] - 超盈国际控股 (02111) reported a volume ratio of 1.71, suggesting increased investor focus [2] Group 3: Companies with Moderate Volume Ratios - 中国能源建设 (03996) had a volume ratio of 1.70, indicating a solid level of trading activity [2] - 亚信科技 (01675) reported a volume ratio of 1.60, reflecting moderate investor interest [2] - 金宝通 (00320) showed a volume ratio of 1.53, suggesting a rise in trading volume [2] Group 4: Companies with Lower Volume Ratios - 中国水务 (00855) had a volume ratio of 1.52, indicating stable trading activity [2] - 广汽集团 (02238) reported a volume ratio of 1.52, reflecting consistent investor engagement [2] - 凯莱英 (06821) showed a volume ratio of 1.52, suggesting steady trading interest [2]

Financial Performance - The company achieved a record revenue of $164.1 million for the fiscal year 2024, representing a growth of 6.6% year-over-year, with an 8.7% increase excluding foreign exchange fluctuations [9]. - Gross profit increased by 7.5% to approximately $114.5 million, with around 1.7 million products sold globally, of which 1.5 million were proprietary products, marking a 4.8% year-over-year increase [9]. - The company reported a decrease in profit attributable to shareholders by 11.9% to $39.7 million, with basic earnings per share at 4.81 cents, down from 5.45 cents in 2023 [10]. - Core operating profit, after excluding stock-based compensation and other adjustments, was $29.0 million, a decline of 15.8% compared to $34.4 million in 2023 [10]. - Revenue increased from $153.9 million in 2023 to $164.1 million in 2024, a growth of $10.2 million or 6.6% [39]. - The net profit attributable to the company's owners decreased by 11.9% to $39.7 million, with basic earnings per share of 4.81 cents, down 11.7% from 5.45 cents in 2023 [22][19]. Revenue Breakdown - Revenue from the Asia-Pacific region reached $52.2 million, a significant increase of 43.7% year-over-year, driven by new acquisitions and strong internal growth [23]. - Revenue from Europe, the Middle East, and Africa grew by 7.9% to $39.2 million, primarily due to increased sales of proprietary balloon products [24]. - Revenue from Japan decreased by 9.4% to $34.4 million, attributed to the depreciation of the yen against the dollar and price adjustments [25]. - Revenue from China showed a reduced decline of 5.4%, with reported income of approximately $20.7 million, following improved marketing strategies [26]. - Revenue from the U.S. market reached $17.5 million, with a decline of 17.7%, narrowing from a 40.9% drop in the first half of the year [27]. Operational Developments - The company is integrating three acquired companies, which will incur additional operational costs but is essential for long-term development [10]. - The company is enhancing automation at its largest R&D production facility in Hangzhou, China, to reduce labor costs and improve operational efficiency [11]. - The group is constructing its largest R&D and manufacturing facility in Hangzhou, China, expected to increase annual production capacity by 2.4 million units upon completion in 2027 [34]. - The group has established a strong quality management system and a solid global presence, selling products in over 70 countries and regions [11]. Shareholder Returns - The company plans to distribute a final cash dividend of HKD 0.10 per share, maintaining the same level as in 2023, to reward shareholders for their continued support [10]. - The group plans to distribute a final cash dividend of HKD 0.10 per share to reward shareholders for their continued support [37]. - The company proposed a final dividend of HKD 0.10 per share for the year ending December 31, 2024, consistent with the previous year [180]. Research and Development - Research and development expenses increased by 18.5% to $17.0 million, primarily due to higher service fees paid to contract research organizations [49]. - The company is focusing on the development and commercialization of new products, with $1.5 million allocated for next-generation neurointerventional products [127]. - The company plans to expand its R&D team in Shenzhen, with $0.7 million allocated for this purpose by the end of 2025 [127]. Market Strategy - A partnership was formed with a well-known Chinese manufacturer to distribute innovative products in the Asia-Pacific market, with plans to expand cooperation to other regions [11]. - The group anticipates revenue growth driven by the Asia-Pacific region and Europe, the Middle East, and Africa, with a focus on launching new products like Teleport Glide and Scoreflex QUAD in the Japanese market [36]. - The company is expanding its market presence in Asia, targeting a 30% increase in market share by the end of the fiscal year [83]. Financial Position - As of December 31, 2024, the group holds over 240 authorized patents and published patent applications globally, with more than 40 and 90 in the United States and China, respectively [30]. - The group has a cash and bank balance of $248.6 million as of December 31, 2024, positioning it well for potential acquisitions and industry consolidation opportunities [36]. - The total current assets amounted to approximately $361.5 million, compared to $348.0 million as of December 31, 2023 [55]. - The total current liabilities as of December 31, 2024, were approximately $30.7 million, down from $35.6 million as of December 31, 2023 [55]. - The current ratio as of December 31, 2024, was approximately 11.8 times, an increase from 9.8 times as of December 31, 2023 [57]. Corporate Governance - The company has adopted corporate governance principles to enhance shareholder value and accountability [199]. - The audit committee has reviewed the consolidated financial statements for the year ended December 31, 2024, and found them compliant with applicable accounting standards [195]. - The auditor, PwC, has audited the financial statements and is eligible for reappointment at the upcoming annual general meeting [196]. - The company is committed to maintaining high standards of corporate governance to protect shareholder interests [200]. Employee and Management - As of December 31, 2024, the company employed 1,331 employees, with employee benefit expenses totaling approximately $59.1 million, up from $53.3 million in 2023, reflecting a year-over-year increase of about 14.0% [113]. - The company has implemented stock option plans and incentive programs to enhance employee performance and retention [113]. - The board of directors includes both executive and independent non-executive members, with specific terms of service ranging from 1 to 3 years [96]. Risks and Compliance - The group has faced various financial risks, including credit risk, liquidity and interest rate risk, and foreign exchange risk, with details provided in the financial risk management section of the annual report [108]. - Legal risks include potential litigation that may involve significant damages, although the company believes it has strong defenses against such claims [110]. - The company is subject to economic sanctions imposed by the U.S., EU, UN, and Australia, which could negatively impact sales to sanctioned countries [111]. - The company has complied with relevant laws and regulations during the reporting period [190].

Core Viewpoint - The percutaneous coronary intervention (PCI) market in China is experiencing significant growth due to increasing rates of cardiovascular diseases driven by aging population and rising obesity rates, with the number of PCI procedures expected to reach 3.6 million by 2030 from 1.9 million in 2024 [1][11]. Industry Overview - PCI is a minimally invasive procedure aimed at improving blood flow in narrowed or blocked coronary arteries, with various techniques including balloon angioplasty and stent implantation [1][5]. - The PCI industry is supported by a supply chain that includes raw materials like stainless steel and cobalt-chromium alloys, as well as advanced medical devices and technologies [5]. Industry Environment - China has approximately 330 million patients with cardiovascular diseases (CVD), with a significant portion being elderly, which correlates with a rising incidence of heart diseases [7]. - The aging population in China is projected to increase from 145 million in 2015 to 220 million by the end of 2024, leading to a higher prevalence of cardiovascular diseases [7]. Industry Status - The total number of registered PCI cases in China reached 1,636,055 in 2023, marking a year-on-year growth rate of 26.44%, the highest recorded [9]. - National policies are enhancing healthcare services and infrastructure, leading to increased accessibility and acceptance of PCI procedures among patients [11]. Development Trends - The PCI industry is witnessing rapid technological innovation and product upgrades, with advancements in drug-eluting stents and biodegradable stents improving treatment outcomes and reducing complications [20]. - Market demand for PCI is expected to continue growing due to rising cardiovascular disease rates and increased public awareness of health [21]. - The industry faces intensified international competition, necessitating domestic companies to enhance innovation and expand into global markets [22]. Competitive Landscape - The PCI market in China is characterized by a mix of international giants like Medtronic and Abbott, and domestic companies such as Lepu Medical and Sino Medical, with the latter gaining market share through competitive pricing and innovative products [15][16]. - Companies like Weimai Medical and Yiju Medical are focusing on comprehensive solutions in interventional devices, with a strong emphasis on research and development [16][18].